Consistently exceeding expectations

M N 10 May 2024 CMB International Global Markets | Equity Research | Company Update BeiGene (BGNE US) Consistently exceeding expectations  Product sales continued beating expectation. In 1Q24, BeiGene recorded total Target Price US$269.73 product sales of US$747mn (+18% QoQ, +82% YoY), representing 25.7% of our (Previous TP US$248.52) previous FY24 estimate. Zanubrutinib (zanu) maintained strong sales momentum, Up/Downside 59.9% with sales increasing 18% QoQ or 131% YoY to US$489mn. The strong Current Pric ...